CME Fundamental Analysis & Score

$270.03
Quote dated October 05, 2026
88/100
Strong Buy

What this score covers. It is a fixed screen of five reported ratios with no valuation input, so a company can score highly while its valuation risk remains elevated. The full report scores valuation separately, as one of nine scored sections. How the score is calculated

View Plans
Page generated: October 06, 2026 at 11:25 UTC

Key Financial Metrics

Market Cap
$97.10B
P/E Ratio (TTM)
22.9x
P/E Forward
20.9x
Revenue Growth
0.8%
Gross Margin
100.0%
Net Margin
63.4%
Return on Equity
15.8%
Debt/Equity
0.15

Rule-Based Financial Screen Summary

CME Group Inc. (CME) is a Financial Services company in the Financial Data & Stock Exchanges industry. It has a 88/100 Strong Buy score on our five-factor fundamentals screen. Key strengths include Gross Margin (100.0%), Net Margin (63.4%), Return on Equity (15.8%). The score is a five-factor screen — revenue growth, gross margin, net margin, return on equity and debt-to-equity — each scored against fixed thresholds from a neutral starting point of 50 points. The full report scores nine sections, including moat, free cash flow, dilution and valuation, which this screen does not.

Revenue Growth: Moderate Gross Margin: Excellent Net Margin: Excellent Return on Equity: Good Debt/Equity: Low Risk

This page score and the strengths and concerns above are produced by deterministic, rule-based calculations from the available third-party financial inputs documented below. AI does not choose the score, strengths, or concerns. Data and automated summaries can contain errors. This is not personalized investment advice. See our methodology and disclaimer.

How this page score was calculated

The calculation starts at 50 points and applies the five fixed adjustments shown below. Missing or invalid inputs contribute no adjustment. A finite provider-reported zero is treated as a measured value and evaluated against that input's displayed threshold. The pre-clamp result is 88; the published result is clamped to a minimum of 10 and maximum of 98, producing 88/100.

CME score inputs and fixed adjustments
Input Displayed value Threshold applied Adjustment Data status
Revenue Growth 0.8% > 0% to 10% +4 Available
Gross Margin 100.0% > 50% +10 Available
Net Margin 63.4% > 20% +10 Available
Return on Equity 15.8% > 12% to 20% +6 Available
Debt/Equity 0.15 < 0.30 +8 Available

Score bands

80 or higher: Strong Buy; 65–79: Buy; 50–64: Hold; below 50: Caution.

These are fixed names for score ranges. The score is not a success probability, recommendation, or forecast, and 80/100 does not mean an 80% chance of a gain.

Not included in this score

  • Peer results or relative peer ranking
  • Demand zones or liquidity
  • Technical momentum
  • News or market sentiment
  • DCF valuation or the downloadable report score

Sources, freshness, and limitations

This page was generated . The provider identifies the latest underlying financial period as June 30, 2026. The displayed market quote is dated October 05, 2026. Generation time is not the same as the date of the underlying filing or market observation.

Financial inputs may be delayed, restated, differently standardized by the data provider, or unavailable. Missing, invalid, or non-finite values receive no positive or negative adjustment rather than being estimated. A finite provider-reported zero is retained and evaluated against that metric's displayed threshold; it is not treated as missing. This can make a sparse-data score less informative. The screen does not capture every business, market, valuation, or portfolio risk, and investors can lose money.

What the full CME report adds

The 88/100 on this page comes from a fixed screen of 5 ratios. The downloadable report is a separate analysis with its own score, built from 9 weighted sections.

This page: fixed screen

  • Revenue Growth
  • Gross Margin
  • Net Margin
  • Return on Equity
  • Debt/Equity

Each factor is scored against fixed thresholds from a starting point of 50 points. No factor prices the stock, so valuation is not part of the 88/100.

Full report: 9 scored sections

  1. Business Moat weight 15 of 100
  2. Revenue Growth Consistency weight 14 of 100
  3. Margin Quality weight 12 of 100
  4. Free Cash Flow Strength weight 12 of 100
  5. Balance Sheet Safety weight 12 of 100
  6. Returns on Capital weight 12 of 100
  7. Dilution vs Self-Funded Growth weight 8 of 100
  8. Valuation vs Growth weight 10 of 100
  9. Structural vs Cyclical Growth weight 5 of 100

When the inputs allow, the report also shows a fair-value estimate with its discounted cash flow (DCF) assumptions and a 3×3 sensitivity table, a confidence figure, and the data limitations that reduced that confidence. Its headline label can add a valuation-risk flag next to the fundamental-quality rating.

Open the CME report page

Supplementary Metrics for CME

4 data points drawn from analyst targets, consensus estimates, and ownership data. These are supplementary observations, not event predictions or causal explanations:

The provider-reported analyst mean target is $284.50 (+5.4% from the displayed price), based on 16 estimates. This is third-party opinion, not a StrongBuyAnalytics target.
The provider-reported third-party analyst consensus category is Buy; it is not a StrongBuyAnalytics recommendation.
The current provider record reports institutional ownership of 91.8%.
The current provider record reports a dividend yield of 1.93%.

CME vs. ICE, SPGI, NDAQ, COIN

Compared against other Financial Data & Stock Exchanges companies we cover, picked for having a similar market capitalisation to CME.

Comparison context only: this peer set is selected statically from our covered companies using industry and company-size context. Peer data and peer selection do not change the CME page score.

Ticker Price Market Cap P/E Rev Growth Net Margin ROE
CME $270.03 $97.10B 22.9x 0.8% 63.4% 15.8%
ICE $152.15 $85.42B 21.5x 4.8% 38.2% 14.1%
SPGI $390.92 $115.24B 23.8x 10.4% 30.5% 14.3%
NDAQ $92.19 $51.53B 26.9x 14.9% 35.0% 16.5%
COIN $188.22 $49.66B — -17.3% -16.3% -7.8%

Risk Indicators for CME

2 measurable indicators visible in CME Group Inc.'s reported numbers. These are market and valuation risk metrics — not a comprehensive list of business risks, which would require qualitative analysis beyond this data:

The provider-reported beta is 0.27. A beta below 1 reflects smaller historical price moves relative to the provider's benchmark; it does not cap future gains or losses.
The provider-reported short ratio is 3.0 days to cover. Short-interest data can be delayed and may reflect hedging or other strategies, so it does not establish investor intent or future direction.

CME Balance Sheet & Cash Flow

CME Group Inc.'s liquidity and cash generation as of the most recent filing — note the cash position of $2.28B against $3.87B of debt:

Total Cash
$2.28B
Total Debt
$3.87B
Current Ratio
1.02
FCF Yield
3.0%
EBITDA
$4.77B
Operating Margin
65.0%

These are provider-normalized figures and may differ from the issuer's as-filed presentation, units, or latest amendment. Use source filings for verification.

CME Valuation Snapshot

Trailing P/E
22.9x
Fairly valued
Forward P/E
20.9x
Earnings growth expected
Price / Book
3.7x
Premium
PEG Ratio
4.58
Expensive vs growth
Analyst Target (Mean)
$284.50
Range: $217 – $330
Dividend Yield
1.93%
5Y avg: 2.90%
52-Week Price Range — CME is trading at 47% of its range
$218.31 (52W Low) $329.16 (52W High)

Who Holds CME? — Institutional 13F Filings

Institutional investment managers with >$100 M in qualifying assets must disclose their equity positions quarterly on SEC Form 13F — typically within 45 days of quarter-end. Search those filings below to see which hedge funds, mutual funds, and asset managers reported CME as a holding, how many shares they held, and how positions changed quarter over quarter.

Search 13F Filings for CME Free · no sign-in required · live SEC EDGAR data
What you see free
Which institutions reported CME, share counts, reported values, and direct links to the SEC filing.
Research Pro adds
Full manager portfolios — every position a fund holds, quarter-over-quarter changes, and concentration weights.
Data limitation
13F reports covered long positions for the filing's stated reporting period, typically a quarter-end—not on its later submission date. Short positions, full derivatives, and current intent are not disclosed.

How to Interpret the CME Fundamentals Score

CME rates 88/100 on our five-factor fundamentals screen, which puts it in the "Strong Buy" band. The band name describes a fixed range in this model; it is not a recommendation or prediction. The calculation above shows how each reported input affected the result.

88/100 · Strong Buy band

CME Group Inc. clears our thresholds on most of what we measure. The strongest readings are gross margin (100.0%) and net margin (63.4%). Nothing in the data we score currently works against it.

CME Earnings & Revenue Outlook

CME Group Inc. reported revenue growth of 0.8% year over year, against a Financial Data & Stock Exchanges peer set where scale and pricing power vary widely. Growth that slow contributes little to the score on its own; margins and capital efficiency carry more weight for CME.

Earnings grew 2.5% over the same period, outpacing revenue — a sign of operating leverage.

Track upcoming report dates on our earnings calendar.

CME Fundamental Factors to Monitor

This is a review of reported fundamentals, not a price target or an estimate of future returns. These are the current figures that may be useful to monitor as new filings become available.

Current reading: Net margins of 63.4% show how much reported revenue currently converts to profit. Future filings may change either figure and the resulting score.

Positive Fundamental Inputs for CME

These are the CME Group Inc. figures that push the score up, taken straight from the most recent reported financials:

  • Gross Margin (100.0%)
  • Net Margin (63.4%)
  • Return on Equity (15.8%)
  • Debt/Equity (0.15)

Learn More About Stock Analysis

Free 14-Min Course
Instructor
StrongBuy Analytics
Fundamental Research Team
How to Read Your Research Report
14Min
15Chapters
FreeNo sign-up

See how the metrics on this CME page — quality score, valuation, DCF scenarios, confidence labels, and data limitations — are organized in the downloadable research report.

Generate My Free CME Report

Guides to the specific measures used in this CME analysis:

Fundamental Analysis Guide

How the financial statements behind this page fit together.

Understanding P/E Ratio

What CME's 22.9x multiple does and does not tell you.

Return on Equity (ROE)

Why CME's 15.8% return on equity matters for stock selection.

Stock Valuation Methods

How DCF, multiples and asset-based approaches value a company like CME Group Inc..

DCF Assumptions and Limitations

What a discounted cash flow estimate for CME depends on, and where it breaks down.

How to Read an AI Stock Report

What each section of a CME report is for, and what it leaves out.

How to Read Earnings Reports

Where the CME growth and margin figures on this page come from.

What Are Demand Zones?

The technical side we deliberately keep out of the CME score.

Related Tools for CME

Semiconductor Demand Zone Tracker CME Live Chart CME SEC Filing News Earnings Calendar Institutional Ownership Sector Scanner Average Down Calculator

CME SEC Filing News

Latest SEC filings for CME explained in plain English — insider buys/sells (Form 4), proposed sales (Form 144), material events (8-K), and quarterly & annual reports.

Loading recent SEC filings…
View all CME SEC Filing News →

Frequently Asked Questions about CME

What are key support and resistance levels for CME?
Support and resistance are technical levels, so they are not part of the fundamentals score. Our demand zones page tracks semiconductor stocks; coverage does not extend to every ticker. Use the chart tool to identify price levels for CME manually.
Which companies are CME's closest peers?
On this page CME is compared with ICE, SPGI, NDAQ, COIN. Compared against other Financial Data & Stock Exchanges companies we cover, picked for having a similar market capitalisation to CME. The table puts CME's a gross margin of 100.0%, an ROE of 15.8%, a debt-to-equity ratio of 0.15 next to the same figures for each peer.
Is the CME analysis PDF report free?
Your first CME report is free and does not require a card. The score on this page is a five-factor screen; the report scores nine sections, adding moat, free cash flow, share dilution and valuation work that is not on this page. Further reports are covered by a subscription; see pricing for the current plans.

This CME analysis is for educational and informational purposes only and does not constitute financial advice. Figures come from third-party feeds and can be delayed, standardized, incomplete, or inaccurate; verify material facts in primary filings and identified sources. Past performance does not guarantee future results. Read our full disclaimer.